Skip to main content

Advertisement

SpringerLink
Log in

Surgical Management of Diabetic Macular Edema

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Diabetic macular edema (DME) is the accumulation of fluid in the extracellular space within the macula and is a major cause of visual impairment among patients with diabetes. First-line treatment for DME includes pharmacotherapy with intravitreal anti-vascular endothelial growth factor medications and intravitreal corticosteroids. Alternative therapeutic strategies include laser photocoagulation for non-center involving DME, and surgical options such as pars plana vitrectomy (PPV) with or without internal limiting membrane (ILM) peel in cases with vitreoretinal interface anomalies or DME refractory to pharmacotherapy, and the Port Delivery System (PDS) for sustained release of anti-vascular endothelial growth factor (VEGF) medication. Our aim is to review the existing literature on surgical management of DME including imaging changes in chronic DME and the clinical relevance of surgical intervention.

Recent Findings

Imaging changes associated with DME and a worse prognosis include disorganization of the retinal layer, disruption of both the external limiting membrane (ELM) and ellipsoid zone, and vitreomacular interface abnormalities. Studies involving pars plana vitrectomy with and without ILM peel show anatomic improvement but may not always be associated with significant change in visual outcomes. Early studies lacked detailed imaging of the retinal layers and PPV was likely performed as a last resort. In addition, the novel PDS is surgically implanted into the pars plana and works as a drug reservoir with controlled release of drug. However, it has been recalled in patients with wet age-related macular degeneration due to issues with dislodgement.

Summary

Surgical interventions for DME include pars plana vitrectomy with and without ILM peel and new surgical therapies for DME such as the PDS and subretinal gene therapy have the potential to reduce the risk of DME progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis [Internet]. 2015;2(1):1–25. Available from: https://doi.org/10.1186/s40662-015-0026-2

  2. •• Baker CW, Glassman AR, Beaulieu WT, Antoszyk AN, Browning DJ, Chalam KV, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA - J Am Med Assoc. 2019;321(19):1880–94. This study provided evidence that patients with DME with good visual acuity can be treated with either intravitreal injections or laser photocoagulation or continued observation with similar outcomes.

  3. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology [Internet]. 2011;118(4):615–25. Available from: https://doi.org/10.1016/j.ophtha.2011.01.031

  4. Chew EY, Clemons TE, Harrington M, Bressler SB, Elman MJ, Kim JE, et al. Effectiveness of different monitoring modalities in the detection of neovascular age-related macular degeneration. Retina [Internet]. 2016 Aug [cited 2018 Mar 1];36(8):1542–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27243927

  5. Shah SU, Maturi RK. Therapeutic options in refractory diabetic macular oedema. Drugs. 2017;77(5):481–92.

    Article  CAS  PubMed  Google Scholar 

  6. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.

    Article  PubMed  Google Scholar 

  7. Santos AR, Costa MA, Schwartz C, Alves D, Figueira J, Silva R, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the CHARTRES study. Retina. 2018;38(6):1110–9.

    Article  CAS  PubMed  Google Scholar 

  8. Radwan SH, Soliman AZ, Tokarev J, Zhang L, Van Kuijk FJ, Koozekanani DD. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol. 2015;133(7):820–5.

    Article  PubMed  Google Scholar 

  9. Das R, Spence G, Hogg RE, Stevenson M, Chakravarthy U. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. JAMA Ophthalmol. 2018;136(2):202–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Maheshwary AS, Oster SF, Yuson RMS, Cheng L, Mojana F, Freeman WR. The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema. Am J Ophthalmol [Internet]. 2010;150(1):63–67.e1. Available from: https://doi.org/10.1016/j.ajo.2010.01.039

  11. Otani T, Yamaguchi Y, Kishi S. Correlation between visual acuity and foveal microstructural changes in diabetic macular edema. Retina. 2010;30(5):774–80.

    Article  PubMed  Google Scholar 

  12. Shen Y, Liu K, Xu X. Correlation between visual function and photoreceptor integrity in diabetic macular edema: spectral-domain optical coherence tomography. Curr Eye Res. 2016;41(3):391–9.

    PubMed  Google Scholar 

  13. Ercalik NY, Imamoglu S, Kumral ET, Yenerel NM, Bardak H, Bardak Y. Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema. Arq Bras Oftalmol. 2016;79(6):373–5.

    Article  PubMed  Google Scholar 

  14. Maryam AK, Tafgeh M, Mahmoud M, Pasha A, Ahad S, Khalil GF. Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane. Rom J Ophthalmol. 2018;62(3):212–6.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Figueroa M, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2008;28(3):420–6.

    Article  PubMed  Google Scholar 

  16. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefe’s Arch Clin Exp Ophthalmol. 2004;242(8):630–7.

    Article  Google Scholar 

  17. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado C, Trempe L, McMeel JW, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95(10):1335–9.

    Article  CAS  PubMed  Google Scholar 

  18. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol. 2005;140(2):295.e1-295.e9.

    Article  Google Scholar 

  19. Kumagai K, Hangai M, Ogino N, Larson E. Effect of internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema. Retina. 2015;35(7):1422–8.

    Article  PubMed  Google Scholar 

  20. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol. 2005;139(5):795–801.

    Article  PubMed  Google Scholar 

  21. Browning D, Lee C, Stewart M, Landers M. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016;10:735–42.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ulrich JN. Pars plana vitrectomy with internal limiting membrane peeling for nontractional diabetic macular edema. Open Ophthalmol J. 2017;11(1):5–10.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Iglicki M, Lavaque A, Ozimek M, Negri HP, Okada M, Chhablani J, et al. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: the vital study. PLoS ONE. 2018;13(7):1–12.

    Article  Google Scholar 

  24. Michalewska Z, Stewart M, Landers M, Bednarski M, Adelman RA, Nawrocki J. Vitrectomy in the management of diabetic macular edema in treatment-naïve patients. Can J Ophthalmol. 2018;53(4):402–7.

    Article  PubMed  Google Scholar 

  25. •• Pessoa B, Afonso Dias D, Baptista P, Coelho C, Beirão JNM, Meireles A. Vitrectomy outcomes in eyes with tractional diabetic macular edema. Ophthalmic Res. 2019;61(2):94–9. This retrospective study demonstrated that PPV for tractional DME showed a reduction in central foveal thickness and increase in visual acuity in more than 50% of cases with low recurrence and postoperative complications, suggesting it could be a reasonable surgical management option for tractional DME.

  26. Thomas D, Bunce C, Moorman C, Laidlaw DAH. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol. 2005;89(1):81–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Patel JI, Hykin PG, Schadt M, Luong V, Bunce C, Fitzke F, et al. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye. 2006;20(8):873–81.

    Article  CAS  PubMed  Google Scholar 

  28. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R. Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefe’s Arch Clin Exp Ophthalmol. 2007;245(3):360–8.

    Article  Google Scholar 

  29. Jackson TL, Nicod E, Angelis A, Grimaccia F, Pringle E, Kanavos P. Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina. 2017;37(5):886–95.

    Article  PubMed  Google Scholar 

  30. Doi N, Sakamoto T, Sonoda Y, Yasuda M, Yonemoto K, Arimura N, et al. Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes. Graefe’s Arch Clin Exp Ophthalmol. 2012;250(1):71–8.

    Article  CAS  Google Scholar 

  31. Nakajima T, Roggia MF, Noda Y, Ueta T. Effect of internal limiting membrane peeling during vitrectomy for diabetic macular edema: systematic review and meta-analysis. Retina. 2015;35(9):1719–25.

    Article  PubMed  Google Scholar 

  32. Hoerauf H, Brüggemann A, Muecke M, Lüke J, Müller M, Stefánsson E, et al. Pars plana vitrectomy for diabetic macular edema. Internal limiting membrane delamination vs posterior hyaloid removal. A prospective randomized trial. Graefe’s Arch Clin Exp Ophthalmol. 2011;249(7):997–1008.

    Article  Google Scholar 

  33. Bardak Y, Çekiç O, Tiǧ ŞU. Comparison of ICG-assisted ILM peeling and triamcinolone-assisted posterior vitreous removal in diffuse diabetic macular oedema. Eye. 2006;20(12):1357–9.

    Article  CAS  PubMed  Google Scholar 

  34. Yamamoto T, Hitani K, Sato Y, Yamashita H, Takeuchi S. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica. 2005;219(4):206–13.

    Article  PubMed  Google Scholar 

  35. Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefe’s Arch Clin Exp Ophthalmol. 2012;250(10):1415–20.

    Article  Google Scholar 

  36. Hagenau F, Vogt D, Ziada J, Guenther SR, Haritoglou C, Wolf A, et al. Vitrectomy for diabetic macular edema: optical coherence tomography criteria and pathology of the vitreomacular interface. Am J Ophthalmol [Internet]. 2019;200:34–46. Available from: https://doi.org/10.1016/j.ajo.2018.12.004

  37. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu AF. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16(4):573–81.

    Article  CAS  PubMed  Google Scholar 

  38. Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008;28(3):410–9.

    Article  PubMed  Google Scholar 

  39. Ichiyama Y, Sawada O, Mori T, Fujikawa M, Kawamura H, Ohji M. The effectiveness of vitrectomy for diffuse diabetic macular edema may depend on its preoperative optical coherence tomography pattern. Graefe’s Arch Clin Exp Ophthalmol [Internet]. 2016;254(8):1545–51. Available from: https://doi.org/10.1007/s00417-015-3251-4

  40. Simunovic MP, Hunyor AP, Ho I-V. Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol. 2014;49(2):188–95.

    Article  PubMed  Google Scholar 

  41. Berrocal MH, Acaba LA, Chenworth ML. Surgical innovations in the treatment of diabetic macular edema and diabetic retinopathy. Curr Diab Rep. 2019;19(10):106.

    Article  PubMed  Google Scholar 

  42. Currie CJ, Peyrot M, Morgan CLL, Poole CD, Jenkins-Jones S, Rubin RR, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35(6):1279–84.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol [Internet]. 2011;56(2):95–113. Available from: https://doi.org/10.1016/j.survophthal.2010.08.006

  44. Singerman LJ, Masonson H, Patel M, Adamis AP, Buggage R, Cunningham E, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF inhibition study in ocular neovascularisation (VISION) trial. Br J Ophthalmol. 2008;92(12):1606–11.

    Article  CAS  PubMed  Google Scholar 

  45. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology [Internet]. 2006;116(1):57–65.e5. Available from: https://doi.org/10.1016/j.ophtha.2008.10.018

  46. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920–7.

    Article  PubMed  Google Scholar 

  47. Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Heal Med. 2018;23(2):127–40.

    Article  Google Scholar 

  48. Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology [Internet]. 2019;126(8):1141–54. Available from: https://doi.org/10.1016/j.ophtha.2019.03.036

  49. Genentech’s Susvimo earns FDA approval [Internet]. Modern Retina. [cited 2022 Apr 24]. Available from: https://www.modernretina.com/view/genentech-s-susvimo-earns-fda-approval

  50. Genentech voluntarily recalls Susvimo ocular implant for wet AMD [Internet]. Eyewire+. 2022 [cited 2022 Feb 10]. Available from: https://eyewire.news/news/genentech-voluntarily-recalls-susvimo-ocular-implant-for-wet-amd?c4src=article:infinite-scroll

  51. Genentech: Press Releases | Wednesday, Jul 25, 2018 [Internet]. [cited 2022 Apr 24]. Available from: https://www.gene.com/media/press-releases/14739/2018-07-25/genentech-unveils-positive-phase-ii-resu

  52. •• Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology [Internet]. 2022;129(3):295–307. Available from: https://doi.org/10.1016/j.ophtha.2021.09.016. Results of the phase 3 clinical trial of Port Delivery System with Ranibizumab for wet AMD showed equivalent treatment as the current standard of monthly injections. Success in his trial has led to the phase 3 trail of the same system in patients with DME.

  53. This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab [Internet]. [cited 2022 Apr 24]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04108156

  54. Chandrasekaran, Priya R Madanagopalan VG. Ranibizumab port delivery system in neovascular age-related macular degeneration. Ther Adv Ophthalmol. 2022;7(14).

  55. El-Mollayess GM, Saadeh JS, Salti HI. Exogenous endophthalmitis in diabetic patients: a systemic review. ISRN Ophthalmol. 2012;2012(456209).

  56. Mukkamala L, Bhagat N, Zarbin MA. Practical lessons from protocol I for the management of diabetic macular edema. Dev Ophthalmol. 2017;60:91–108.

    Article  PubMed  Google Scholar 

  57. Maturi RK, Glassman AR, Josic K, Antoszyk AN, Blodi BA, Jampol LM, et al. Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–12.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Campbell J, Cole AL, Almony A, Ingraham H, Holekamp NM, Marks S, et al. Real world vision outcomes in DME treated with anti-VEGF injections-an analysis of EMR data from a large health system. Invest Ophthalmol Vis Sci. 2014;55(13):3065–3065.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of North Carolina-Chapel Hill, Chapel Hill, NC, USA

    Jamie Prince, Dipen Kumar & Alice Yang Zhang

  2. Department of Ophthalmology, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA

    Arko Ghosh

  3. Department of Ophthalmology, The Johns Hopkins University School of Medicine, Wilmer Eye Institute, Baltimore, MD, USA

    J. Fernando Arevalo

Authors
  1. Jamie Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dipen Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arko Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Fernando Arevalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alice Yang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Yang Zhang.

Ethics declarations

Conflict of Interest

Jamie Prince, Dipen Kumar, Arko Ghosh, Alice Yang Zhang, declare that they have no conflict of interest.

J. Fernando Arevalo received research funding from Topcon Medical Systems Inc. and royalties from Springer SBM LLC and Elsevier. He has received consulting fees from Abbvie, Genentech, THEA laboratories, DORC, EyePoint Pharmaceuticals and Alimera Sciences, Inc.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prince, J., Kumar, D., Ghosh, A. et al. Surgical Management of Diabetic Macular Edema. Curr Diab Rep 23, 119–125 (2023). https://doi.org/10.1007/s11892-023-01505-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-023-01505-3

Keywords

Search

Navigation